ロード中...
Does it help that efficacy has been proven once we start discussing (added) benefit?
Since the introduction of benefit assessment to support reimbursement decisions in Germany there seems to be the impression that totally distinct methodology and strategies for decision making would apply in the field of drug licensing and reimbursement. In this article, the position is held that, w...
保存先:
| 出版年: | Biom J |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4758384/ https://ncbi.nlm.nih.gov/pubmed/26140608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bimj.201400017 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|